Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Netherlands

European Innovation Council · Running

VitaDisc A novel non-invasive therapy based on injectable viscous gel for restoring the natural biomechanics of the spine and relieving patients from pain

Coordinator
Nc Biomatrix BV, Netherlands
Runs
1 June 2023 to 30 September 2025
Status
Running
EU funding
€2.5m
Total cost
€5.2m
Partners
1 organisations in 1 countries
Type
European Innovation Council
Grant agreement
190168073

What the project is doing

In the project's own words, from its summary on CORDIS.

Over 400 million people globally suffer from back pain. Disc degeneration disease is the prevalent cause of back pain and it is responsible for high social and economic costs. Current treatments are only symptomatic (physiotherapy, pain management or surgery), but they do not regenerate the disc and its function. At NC Biomatrix, we have developed VitaDisc, the first non-invasive early restorative treatment for disc degeneration that has the power to revolutionise the orthopaedics market.

It is an acellular porcine-derived injectable biomatrix that restores disc height, provides optimal support to regenerate the disc, and aids in restoring healthy spinal biomechanics. Its mode of action is fully mechanical, and it can be easily administered in an outpatient setting, giving it a unique market advantage. Our biomatrix platform technology is readily scalable and provides a pipeline of further products for unmet needs in orthopaedic treatments, such as early-stage knee joint arthritis.

Topics

Who is involved

OrganisationCityCountryRole
Nc Biomatrix BVEindhovenNetherlandsCoordinator

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI